Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...
If you’ve recently been diagnosed with multiple sclerosis (MS), chances are you have the relapsing-remitting form of the disease (often abbreviated as RRMS). This form of MS is characterized by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results